x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012064
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val668 of human GLDC protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | GLDC |
| UniProt No. | P23378 |
| Gene ID | 2731 |
| Gene Description | Glycine decarboxylase is a component of a mitochondrial protein complex that catalyzes the degradation of glycine. The glycine cleavage system is composed of three distinct enzymes and an additional component that transfers a glycine methylamine group from one enzyme to another. The GLDC protein is the decarboxylase that binds the methylamine group for transfer to the T-protein. Tumor-initiating cells in the primary non-small cell lung cancer express high levels of GLDC and LIN28B, both of which are essential for the proliferation of tumor-initiating cells. GLDC is an oncogene that promotes tumorigenesis through its metabolic activity. Mutations in the corresponding GLDC gene account for the majority of reported cases of glycine encephalopathy, which is a metabolic disorder characterized by the accumulation of glycine, lethargy, hypotonia, intractable seizures, and death. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
